Self-Reported Nonadherence with Antiretroviral Drugs Predicts Persistent Condition

REFERENCES

• Carpenter CC, Cooper DA, Fischi MA, et al. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381–390.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr L, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• Arnsten J, Demas P, Gourevitch M, et al. Adherence and viral load in HIV-infected drug users: Comparison of self-report and medication event monitors (MEMS). Presented at: 7th Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, California. Abstract 69.
   Google Scholar
• Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569–571.
   PubMed Web of Science ®Google Scholar
• Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276:1955–1956.
   PubMed Web of Science ®Google Scholar
• Murri R, Antinori A, Ammassari A. L'aderenza ai farmaci antiretrovirali. //Pensiero Scientifico Ed. 2000.
   Google Scholar
• Murri R, Ammassari A, Gallicano K, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr. 2000;24:123–128.
   PubMed Web of Science ®Google Scholar
• Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786–798.
   PubMed Web of Science ®Google Scholar
• Whalen CC, Antani M, Carey J, Landefeld CS. An index of symptoms for infection with human immunodeficiency virus: Reliability and validity. J Clin EpidemioL 1994;47:537–546.
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study. Coordinamento Italian° Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr. 2000;23:236–245.
   PubMed Web of Science ®Google Scholar
• Cunningham WE, Shapiro MF, Hays RD, et al. Constitutional symptoms and health-related quality of life in patients with symptomatic HIV disease. Am J Med. 1998;104:129–136.
   PubMed Web of Science ®Google Scholar
• Wilson IB, Cleary PD. Clinical predictors of functioning in persons with acquired immunodeficiency syndrome. Med Care. 1996;34:610–623.
   PubMed Web of Science ®Google Scholar
• Kastrissios H, Suarez JR, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS. 1998;12:2295–2303.
   PubMed Web of Science ®Google Scholar
• Chesney MA, Ickovics J, Hecht FM, Sikipa G, Rabkin J. Adherence: A necessity for successful HIV combination therapy. AIDS. 1999;13:S271–S278.
   PubMed Web of Science ®Google Scholar
• Kastrissios H, Suarez JR, Hammer S, Katzenstein D, Blaschke TF. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentra-tions as a marker. AIDS. 1998;12:2305–2311.
   PubMed Web of Science ®Google Scholar
• Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763–1769.
   PubMed Web of Science ®Google Scholar
• Mehta S, Moore RD, Graham NM. Potential factors affect-ing adherence with HIV therapy. AIDS. 1997;15(11):1665–1670.
   Web of Science ®Google Scholar
• Montessori V, Heath KV, Yip B, et al. Predictors of adher-ence with triple combination antiretroviral therapy. Pre-sented at: 7th Conference on Retroviruses and Opportu-nistic Infections; January 2000; San Francisco, California. Abstract 72.
   Google Scholar
• Moatti JP, Carrieri MP, Spire B, et al. Adherence to HAART in French HIV-infected injecting drug users: The contribu-tion of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS. 2000;14:151–155.
   PubMed Web of Science ®Google Scholar
• d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14:499-507.
   PubMed Web of Science ®Google Scholar
• Leider JM, Kalkut G. Understanding adherence to HIV medication. Ann Intern Med. 2000;132:418.
   PubMed Web of Science ®Google Scholar
• Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontin-ued? J Acquir Immune Defic Syndr Hum Retrovirol. 1999;21:114–119.
   Google Scholar
• Justice AC, Rabeneck L, Hays RD, Wu AW, Bozzette SA. Sensitivity, specificity, reliability, and clinical validity of pro-vider-reported symptoms: A comparison with self-reported symptoms. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;21:126–133.
   Google Scholar
• Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in pre-dicting virologic and immunologic response. AIDS. 1999;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Hecht FM, Colfax G, Swanson M, Chesney M. Adherence and effectiveness of protease inhibitors in clinical practice. Presented at: 5th Conference on Retroviruses and Oppor-tunistic Infections; February 1998; Chicago, Illinois.
   Google Scholar
• Nieuwkerk P, Burger D, Hugen P, et al. Patient adherence to highly active antiretroviral therapy for HIV-1 infection in a nation-wide cohort study in the Netherlands. Presented at: First ICONA Conference; June 22–23, 2000; Baveno.
   Google Scholar